載入...

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. For this evaluation, we employed our hollow-fiber infection...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Drusano, G. L., Sgambati, Nicole, Eichas, Adam, Brown, David L., Kulawy, Robert, Louie, Arnold
格式: Artigo
語言:Inglês
出版: American Society of Microbiology 2010
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2925073/
https://ncbi.nlm.nih.gov/pubmed/20802826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/mBio.00139-10
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!